SNDX Q2 2020 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$17M-4382.6% margin

Net Income

-$17M-4501.8% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$193M

Total Liabilities

$45M

Stockholders' Equity

$148M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$17M	-$15M	-8.0%
Net Income	-$17M	-$15M	-14.4%